PDA

View Full Version : Palomar To Debut New Technology At The American Academy Of Dermatology Annual Meeting



Medical Videos
02-14-2008, 09:59 PM
Palomar Medical Technologies, Inc. (Nasdaq: PMTI), a leading researcher and developer of light-based systems for cosmetic treatments, announced that it will unveil two new fractional handpieces at the 66th Annual Meeting of the American Academy of Dermatology (AAD) in San Antonio, Texas from February 2nd to 4th.

Palomar's new Lux2940(TM) fractional ablative laser handpiece is a sophisticated, single-treatment skin resurfacing device which allows the practitioner to tailor the level of skin tightening based on the patient's needs. Three treatment modes are available: short pulse for pure ablation with the fastest treatment times and quickest recovery; long pulse for more coagulation around the ablation columns; and a dual mode for a short pulse / long pulse automatic sequence for deeper corrections. The Lux2940(TM) microfractional technology preserves portions of healthy tissue surrounding the treatment zone, fostering unprecedented rates of reepithelialization and lower patient downtime, with significantly less pain than traditional ablative laser procedures.

Palomar's other new handpiece, the Lux1440(TM) is a fractional, non- ablative skin resurfacing handpiece that operates much like the popular Lux1540(TM), but with faster treatment times. Specifically, licensed practitioners are performing effective full-face treatments in about 12 minutes. As compared to other skin resurfacing devices, the Lux1440(TM) is perfect for a series of "gentler" skin resurfacing treatments, where patient comfort is a priority and little to no downtime a must.

Both the Lux2940(TM) handpiece and the Lux1440(TM) handpiece operates with the StarLux(R) 500 Laser and Pulsed Light System, a single platform with a full suite of aesthetic applications including hair removal, leg vein clearance, acne management and pigmented lesion treatments, and fractional non-ablative skin resurfacing.

Chief Executive Officer Joseph P. Caruso commented, "We are very excited about these new product introductions, which not only reflect the advancement of Palomar technology, but compliment our existing suite of products. Fractional technology continues to provide superior results and now with both ablative and non-ablative options, patients are able to independently select a treatment modality that fits their lifestyle. Our desire to provide the best user experience, facilitated and supported by our ongoing investment in technology, is a primary driver for Palomar. We believe there is a great need for this technology and will continue to produce innovative and reliable products that meet the demands of our customers."

About Palomar Medical Technologies Inc: Palomar is a leading researcher and developer of light-based systems for cosmetic treatments. Palomar pioneered the optical hair removal field, when, in 1997, it introduced the first high-powered laser hair removal system. Since then, many of the major advances in light-based hair removal have been based on Palomar technology. In December 2006, Palomar became the first company to receive a 510(k) over-the- counter (OTC) clearance from the United States Food and Drug Administration (FDA) for a new, patented, home use, light-based hair removal device. OTC clearance allows the product to be marketed and sold directly to consumers without a prescription. There are now millions of light-based cosmetic procedures performed around the world every year in physician offices, clinics, spas and salons. Palomar is testing many new and exciting applications to further advance the hair removal market and other cosmetic applications. Palomar is focused on developing proprietary light-based technology for introduction to the mass markets. Palomar has an agreement with The Gillette Company to develop and commercialize home-use, light-based devices for women for hair removal and an agreement with Johnson & Johnson Consumer Companies to develop and potentially commercialize home-use, light- based devices for reducing or reshaping body fat including cellulite, reducing the appearance of skin aging, and reducing or preventing acne.

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on the Company's current expectations, plans, intentions, beliefs or predictions. These forward-looking statements are neither promises nor guarantees, but involve risk and uncertainties that may individually or mutually impact the matters herein, and cause actual results, events and performance to differ materially from such forward-looking statements. These risk factors include, but are not limited to, results of future operations, technological difficulties in developing or introducing new products, the results of future research, lack of product demand and market acceptance for current and future products, the effect of economic conditions, challenges in managing joint ventures and research with third parties and government contracts, the impact of competitive products and pricing, governmental regulations with respect to medical devices, including whether FDA clearance will be obtained for future products and additional applications, the results of litigation, including patent infringement lawsuits, difficulties in collecting royalties, potential infringement of third-party intellectual property rights, factors affecting the Company's future income and resulting ability to utilize its NOLs, and/or other factors, which are detailed from time to time in the Company's SEC reports, including the report on Form 10-K for the year ended December 31, 2006 and the Company's quarterly reports on Form 10-Q. Readers are cautioned not to place undue reliance on these forward- looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

Palomar Medical Technologies, Inc.
http://www.palomarmedical.com (http://www.palomarmedical.com/)